The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated (Wild Type) Patients Treated With Erlotinib (TARceva) After the Failure of at Least One Chemotherapy Regimen
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2016
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms STAR
- Sponsors Roche
- 01 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2013 New trial record